GM Medical A/S, a Danish-owned company, is pleased to announce its recent acquisition by Simonsen & Weel (S&W) – Diploma PLC company. This significant development, which was advised by Translink Corporate Finance in Denmark, has led to GM Medical’s inclusion within the esteemed Diploma Healthcare Group, operating within the Life Sciences sector.
Translink Corporate Finance United Kingdom is delighted to have acted as lead advisor to chemical solutions provider Airedale Group on its acquisition of McCann Chemicals, as part of its strategy for growth and diversification.
The acquisition includes subsidiary companies Hunter Chemicals and McCann Food and Nutrition and is Airedale’s third acquisition since 2015. McCann Chemicals will operate as an independent brand within Airedale’s specialist distribution division and opens up new products, notably in the food ingredients space as well as a number of other synergies for the combined group.
Leading independent M&A advisory firms BHP Corporate Finance and IMA Corporate Finance are collaborating and have officially changed their names to Translink Corporate Finance.
Translink, The leading mid-market corporate financial advisory firm, has over 300 experts covering more than 35 countries on six continents. It’s this international footprint of teams with deep local market knowledge and specialised sector expertise that enables Translink to identify M&A opportunities across the globe for clients.
Translink Corporate Finance BHP, based in the UK, acted as the exclusive advisor to the shareholders of EPMS Supplies on the sale to the management team.
BHP LLP has advised EPMS for more than a decade, providing a range of accountancy, audit, and taxation advisory services to support the company in its growth.
Translink Corporate Finance in the UK advised a rapidly growing contract research organisation, Peak Proteins, on the 100% sale to a leading independent integrated drug discovery and non-clinical services company, Sygnature Discovery.
Translink Corporate Finance announces the sale of Universal Security Systems (USS), a European Security Systems Specialist headquartered in London with offices in Finland and Denmark, to Convergint, a global leader in service based systems integration. Translink acted as the exclusive financial adviser to the shareholders of Universal Security Systems.
Translink Corporate Finance announced the sale of Swinton Technology, a market leader in metering supervisory systems and measurement expertise in the oil & gas industry, to Sensia, an automation specialist in oil & gas production, transportation and processing.
BHP Corporate Finance, a Translink Corporate Finance partner in the UK, advised workplace software provider, UMA in becoming one of the first recipients of Finance Yorkshire’s Seedcorn fund.
HegenbergerSpeculum ApS is a supplier of obstetric speculums specifically designed for after-birth repair of vaginal injuries. Approximately 50% of women suffer from this condition and require suturing after giving birth.
Translink Corporate Finance announced the sale of Centaur Healthcare Limited (trading as “Surepharm”), a contract development manufacturing organisation predominantly servicing the pharmaceutical market, to Chiltern Capital, an ambitious and active private equity investor in the UK lower mid-market. Souters Investments and Bluester Capital co-invested alongside Chiltern with debt financing being provided by Thincats. Surepharm provides a wide range of services from pilot plant facilities for formulation development and pre-production trials to outsourced development, manufacturing and packaging of its products for its customers in the UK and overseas. From its fully licensed and high tech facilities, Surepharm specialises in producing solid dose tablets and capsules including controlled drugs, niche medicines and specials for the human and veterinary markets. Chiltern’s investment will support Surepharm to expand the capacity and capabilities of the company to drive faster growth and enhance its formulation and development offerings. Through the provision of funding for capex investment into new dosage forms alongside the development of the sales and marketing functions, Surepharm will develop its capability to provide an end-to-end service for both new and existing customers. At Translink we are aware that the pharmaceuticals and healthcare market is very active and continues to provide exceptional investment opportunities for investors. Our healthcare experience across many countries/continents means we are ideally positioned in all markets to help other healthcare companies and investors accomplish their strategic M&A goals.
Translink UK is an active and very experienced M&A advisor comprising over 20 individuals across four locations. They work extensively on cross border transactions across a number of sectors. A breadth and depth of experience including industrial positions and within private equity underpins a real focus on client outcomes and drives the effective and practical delivery of corporate transactions.
